1. Home
  2. SLN vs LGI Comparison

SLN vs LGI Comparison

Compare SLN & LGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Silence Therapeutics Plc American Depository Share

SLN

Silence Therapeutics Plc American Depository Share

HOLD

Current Price

$6.91

Market Cap

236.2M

Sector

Health Care

ML Signal

HOLD

LGI

Lazard Global Total Return and Income Fund

N/A

Current Price

$17.55

Market Cap

226.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SLN
LGI
Founded
1994
2004
Country
United Kingdom
United States
Employees
116
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
236.2M
226.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SLN
LGI
Price
$6.91
$17.55
Analyst Decision
Buy
Analyst Count
5
0
Target Price
$42.60
N/A
AVG Volume (30 Days)
206.4K
65.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
7.10%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.97
$13.95
52 Week High
$7.83
$19.88

Technical Indicators

Market Signals
Indicator
SLN
LGI
Relative Strength Index (RSI) 71.02 29.10
Support Level $5.79 $17.19
Resistance Level $7.40 $17.75
Average True Range (ATR) 0.63 0.31
MACD 0.18 -0.23
Stochastic Oscillator 68.64 0.43

Price Performance

Historical Comparison
SLN
LGI

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About LGI Lazard Global Total Return and Income Fund

Lazard Global Total Return & Inc Fd Inc is a United States-based diversified, closed-end management investment company. Its investment objective is total return consisting of capital appreciation and income. The fund's portfolio of investments consists of different sector investments such as consumer staples, financials, consumer discretionary, healthcare, materials, sovereign debt and others.

Share on Social Networks: